

## REQUEST FOR INSITU HYBRIDIZATION TESTING OF ADVANCED ADENOCARCINOMA OF THE STOMACH and GASTRO-OESOPHAGEAL JUNCTION



PATIENT DETAILS: Sumame:	REQUESTING PATHOLOGIST: Name:
First Name:	Laboratory:
Address: Postcode:	Address:Postcode:
D.O.B:/	Provider No:
Medicare Number:	Tel:
(Funded by MBS as at 1/01/2016)	Fax: Requesting Dr Signature:
CLINICAL INFORMATION:	Date of request:/// COPY TO:
	Name:
Advanced Gastric Cancer: (please tick one box)  Yes No	Tel: Fax:
Tumour Type: (please tick one box)  Advanced adenocarcinoma of the stomach Gastro-oesophageal junction cancer  Specimen: (please tick one box) Biopsy Excision Other: (please specify)	PLEASE SEND THIS FORM IN A PADDED BAG, ALONG WITH:  1. 5 unstained 4µm sections on coated slides  OR  a paraffin block containing tumour tissue  AND
LABORATORY INFORMATION:  HER2 immunohistochemistry result as per  ToGA* criteria: (please tick one box)  3+  2+  1+  0  Not Performed  Laboratory performing IHC:	2. a copy of the pathology report to: Anatomical Pathology Pathology Queensland Princess Alexandra Hospital Ipswich Rd Woolloongabba QLD 4102 Phone: 07 3176 2415

## **EXPLANATORY NOTES:**

As of 1 January 2016 the MBS are funding HER2 ISH testing for Adenocarcinoma of Stomach or Gastro-Oesophageal junction with metastasis for Trastuzumab under the PBS (Item 73342)

To meet Medicare funding criteria HER2 ISH testing will only be performed on cases of HER2 IHC over expression (Score 2+ or 3+)

HERCEPTIN is indicated in combination with cisplatin and either capecitabine or 5-FU for the treatment of patients with HER2 positive advanced adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease

The diagnosis of advanced destric cancer is at the discretion of the encologist, however as a guide - Inoperable Stage IIIa, Stage IIIb and Stage IV.

Anti-cancer Treatment refers to the use of chemotherapy agents.